Skip to main content
. 2017 Sep 5;114(38):10202–10207. doi: 10.1073/pnas.1704961114

Fig. S5.

Fig. S5.

Receiver operator characteristic (ROC) curves for KRAS mutations (A), CA19-9 (B), CEA (C), HGF (D), OPN (E), and the combination assay (F). (A–E) ROC curves demonstrate the performance of each combination assay biomarker individually. The red points on the curves indicate the marker performance at the thresholds used in the combination assay. Error bars represent 95% CIs for sensitivity and specificity at the particular threshold (red font). (F) ROC curves demonstrating the performance of the combination assay when the KRAS threshold was varied and CA19-9, CEA, HGF, and OPN thresholds were fixed at the levels used in the combination assay (black curve), the CA19-9 threshold was varied and KRAS, CEA, HGF, and OPN thresholds were fixed at the levels used in the combination assay (red curve), the CEA threshold was varied and KRAS, CA19-9, HGF, and OPN thresholds were fixed at the levels used in the combination assay (blue curve), the HGF threshold was varied and KRAS, CA19-9, CEA, and OPN thresholds were fixed at the levels used in the combination assay (green curve), and the OPN threshold was varied and KRAS, CA19-9, CEA, and HGF thresholds were fixed at the levels used in the combination assay (orange curve). The intersection of these three curves designates the overall performance of the triplex assay (64% sensitivity, 99.5% sensitivity).